FLT4 antibody

Catalog No. ABIN1589703

This anti-FLT4 antibody is a Mouse Monoclonal antibody detecting FLT4 in WB, IHC and ELISA. Suitable for Human. This Primary Antibody has been cited in 1 publication.

Quick Overview for FLT4 antibody (ABIN1589703)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FLT4 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Clone: 9D9

Product Details anti-FLT4 Antibody

Purpose: VEGFR-3/FLT-4 antibody

Specificity: Recombinant human soluble VEGFR-3/FLT-4

Cross-Reactivity (Details): The antibody will detect native human VEGFR-1/Flt-1 in ELISA experiments, WB, IF and IP.

Characteristics: Chromosomal location: 5q35.3
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (recombinant human VEGFR-3/FLT-4) extracellular domain.

Purification: Protein-G affinity chromatography

Immunogen: Recombinant human soluble VEGFR-3/FLT-4

Isotype: IgG1

Application Details

Application Notes: ELISA: Use at 1-5 μg/mL, Western Blot: Use at 1-5 μg/mL, IF/ IHC: Use at 1-10 μg/mL.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handling Advice: Centrifuge vial prior to opening.

Storage: 4 °C,-20 °C

Storage Comment: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Expiry Date: 24 months

References for anti-FLT4 antibody (ABIN1589703)

Rohringer, Holnthoner, Hackl, Weihs, Rünzler, Skalicky, Karbiener, Scheideler, Pröll, Gabriel, Schweighofer, Gröger, Spittler, Grillari, Redl: "Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE, Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).

Target Details for FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR-3/FLT-4

Background: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.

Gene ID: 2324

NCBI Accession: NM_002020, NP_002011

UniProt: P35916

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling